ID   NCI-H524
AC   CVCL_1568
SY   H524; H-524; NCIH524
DR   BTO; BTO:0004825
DR   CLO; CLO_0008095
DR   EFO; EFO_0002296
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5831
DR   BioSample; SAMN03472976
DR   BioSample; SAMN10988203
DR   cancercelllines; CVCL_1568
DR   CCRID; 1101HUM-PUMC000356
DR   Cell_Model_Passport; SIDM01129
DR   ChEMBL-Cells; CHEMBL3308296
DR   ChEMBL-Targets; CHEMBL2366342
DR   CLS; 305120
DR   Cosmic; 688024
DR   Cosmic; 844555
DR   Cosmic; 850442
DR   Cosmic; 877208
DR   Cosmic; 877358
DR   Cosmic; 908483
DR   Cosmic; 980933
DR   Cosmic; 1032399
DR   Cosmic; 1152472
DR   Cosmic; 1759289
DR   Cosmic; 1891904
DR   Cosmic; 2125200
DR   Cosmic-CLP; 908483
DR   DepMap; ACH-000816
DR   EGA; EGAS00001000978
DR   GDSC; 908483
DR   GEO; GSM169442
DR   GEO; GSM170710
DR   GEO; GSM170712
DR   GEO; GSM171880
DR   GEO; GSM171881
DR   GEO; GSM794292
DR   GEO; GSM845548
DR   GEO; GSM887435
DR   GEO; GSM888515
DR   GEO; GSM1670249
DR   IARC_TP53; 21575
DR   IGRhCellID; NCIH524
DR   KCB; KCB 2010137YJ
DR   KCLB; 90524
DR   LiGeA; CCLE_825
DR   LINCS_LDP; LCL-1857
DR   PharmacoDB; NCIH524_1119_2019
DR   PRIDE; PXD011896
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1568
DR   PubChem_Cell_line; CVCL_1568
DR   Wikidata; Q54908075
RX   PubMed=1320893;
RX   PubMed=1845952;
RX   PubMed=2388294;
RX   PubMed=2473086;
RX   PubMed=2985257;
RX   PubMed=2985258;
RX   PubMed=3335022;
RX   PubMed=6713399;
RX   PubMed=7720728;
RX   PubMed=8806092;
RX   PubMed=8806103;
RX   PubMed=11030152;
RX   PubMed=17426248;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30038707;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 100 hours (PubMed=25984343).
CC   HLA typing: A*01:01,01:01; B*08:01,39:09; C*07:01,07:01 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000127327; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Asn (c.464C>A); ClinVar=VCV000406564; Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.55%; Native American=0%; East Asian, North=1.32%; East Asian, South=0%; South Asian=0%; European, North=66.11%; European, South=32.01% (PubMed=30894373).
CC   Discontinued: KCLB; 90524; probable.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 12,13
ST   D19S433: 16
ST   D21S11: 29,30
ST   D2S1338: 16,17
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 11,12
ST   D8S1179: 13,15
ST   FGA: 21,22,25 (CCRID)
ST   FGA: 25 (PubMed=25877200)
ST   Penta D: 12,13
ST   Penta E: 5,15
ST   TH01: 8,9.3
ST   TPOX: 8,10
ST   vWA: 14,17
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   PubMed=1320893; DOI=10.1159/000163712;
RA   Verbeeck M.A.E., Elands J.P.M., de Leij L.F.M.H., Buys C.H.C.M.,
RA   Carney D.N., Bepler G., Roebroek A.J.M., van de Ven W.J.M.,
RA   Burbach J.P.H.;
RT   "Expression of the vasopressin and gastrin-releasing peptide genes in
RT   small cell lung carcinoma cell lines.";
RL   Pathobiology 60:136-142(1992).
//
RX   PubMed=1845952; DOI=10.1002/1097-0142(19910201)67:3<619::AID-CNCR2820670317>3.0.CO;2-Y;
RA   Broers J.L.V., Mijnheere E.P., Rot M.K., Schaart G., Sijlmans A.,
RA   Boerman O.C., Ramaekers F.C.S.;
RT   "Novel antigens characteristic of neuroendocrine malignancies.";
RL   Cancer 67:619-633(1991).
//
RX   PubMed=2388294; DOI=10.1093/jnci/82.17.1420;
RA   McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C.,
RA   Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.;
RT   "Metabolic activation of 4-ipomeanol in human lung, primary pulmonary
RT   carcinomas, and established human pulmonary carcinoma cell lines.";
RL   J. Natl. Cancer Inst. 82:1420-1426(1990).
//
RX   PubMed=2473086; DOI=10.1242/jcs.91.1.91;
RA   Broers J.L.V., Rot M.K., Oostendorp T., Bepler G., de Leij L.F.M.H.,
RA   Carney D.N., Vooijs G.P., Ramaekers F.C.S.;
RT   "Spontaneous changes in intermediate filament protein expression
RT   patterns in lung cancer cell lines.";
RL   J. Cell Sci. 91:91-108(1988).
//
RX   PubMed=2985257;
RA   Carney D.N., Gazdar A.F., Bepler G., Guccion J.G., Marangos P.J.,
RA   Moody T.W., Zweig M.H., Minna J.D.;
RT   "Establishment and identification of small cell lung cancer cell lines
RT   having classic and variant features.";
RL   Cancer Res. 45:2913-2923(1985).
//
RX   PubMed=2985258;
RA   Gazdar A.F., Carney D.N., Nau M.M., Minna J.D.;
RT   "Characterization of variant subclasses of cell lines derived from
RT   small cell lung cancer having distinctive biochemical, morphological,
RT   and growth properties.";
RL   Cancer Res. 45:2924-2930(1985).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=6713399;
RA   Rosen S.T., Mulshine J.L., Cuttitta F., Fedorko J., Carney D.N.,
RA   Gazdar A.F., Minna J.D.;
RT   "Analysis of human small cell lung cancer differentiation antigens
RT   using a panel of rat monoclonal antibodies.";
RL   Cancer Res. 44:2052-2061(1984).
//
RX   PubMed=7720728;
RA   Senden N.H.M., van de Velde H.J.K., Broers J.L.V., Timmer E.D.J.,
RA   Kuijpers H.J.H., Roebroek A.J.M., Van de Ven W.J.M., Ramaekers F.C.S.;
RT   "Subcellular localization and supramolecular organization of
RT   neuroendocrine-specific protein B (NSP-B) in small cell lung cancer.";
RL   Eur. J. Cell Biol. 65:341-353(1994).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=8806103; DOI=10.1002/jcb.240630516;
RA   Johnson B.E., Russell E., Simmons A.M., Phelps R.M., Steinberg S.M.,
RA   Ihde D.C., Gazdar A.F.;
RT   "MYC family DNA amplification in 126 tumor cell lines from patients
RT   with small cell lung cancer.";
RL   J. Cell. Biochem. 63 Suppl. 24:210-217(1996).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=17426248; DOI=10.1158/1541-7786.MCR-06-0367;
RA   Olejniczak E.T., Van Sant C., Anderson M.G., Wang G., Tahir S.K.,
RA   Sauter G., Lesniewski R., Semizarov D.;
RT   "Integrative genomic analysis of small-cell lung carcinoma reveals
RT   correlates of sensitivity to bcl-2 antagonists and uncovers novel
RT   chromosomal gains.";
RL   Mol. Cancer Res. 5:331-339(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30038707; DOI=10.18632/oncotarget.25642;
RA   Du L.-Q., Zhao Z.-Z., Suraokar M.B., Shelton S.S., Ma X.-Y., Hsiao T.-H.,
RA   Minna J.D., Wistuba I.I., Pertsemlidis A.;
RT   "LMO1 functions as an oncogene by regulating TTK expression and
RT   correlates with neuroendocrine differentiation of lung cancer.";
RL   Oncotarget 9:29601-29618(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//